Truist raised the firm’s price target on BridgeBio (BBIO) to $80 from $66 and keeps a Buy rating on the shares. The firm has updated its model to reflect Attruby performance in Q3, positive Phase 3 data in ribitol in LGMD2I/R9, and positive Phase 3 data in encaleret in ADH1, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO: